Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits (COACH)

This study is exploring how to improve prescribing for people with chronic obstructive pulmonary disease (COPD) in primary care. COPD is a long-term lung condition. Guidelines recommend the most effective inhalers for different patient groups, but in practice, some patients still receive treatments that are less effective or no longer recommended.

One proven way to support better prescribing is "audit and feedback." This involves giving GP practices reports showing how their prescribing compares with guidance and with other practices. Audit and feedback can change behaviour, particularly when focused on medicines and when practices have scope to improve.

In West Yorkshire, the NHS Integrated Care Board (ICB) is running a quality improvement project (QIP) to reduce inappropriate prescribing in COPD. Every GP practice already receives regular feedback reports. This study will run within that project.

The research will test whether the type of email sent with these reports influences prescribing. Practices will be randomly assigned to one of two groups:

• Personalised emails: highlighting their own performance, recognising progress, and giving practical suggestions.
• Generic emails: a simple notification that the report is available, with no tailored advice.

All practices will receive the same reports, seven times over one year; only the email wording will differ.

The main outcome will be the change in how many COPD patients are prescribed inhalers that combine a long-acting beta agonist and inhaled corticosteroid (LABA/ICS), which are no longer recommended in COPD. Secondary outcomes will include other COPD prescribing measures identified by a clinical expert panel. The study will also explore factors that might influence effectiveness, such as practice size, deprivation, and COPD caseload.

Data will come from existing NHS sources. The ICB already collects anonymised prescribing data for improvement work. For this study, the data will be pseudonymised so researchers cannot identify practices. The University of Leeds will analyse the results, but the research team will not know which code relates to which practice.

This study will not change patient care directly. All patients will continue with their usual GP treatment. The aim is to understand whether small changes in delivering audit and feedback make it more effective in supporting best prescribing. In the long term, this could improve the safety and quality of COPD care.

Study Overview

• Status: Active, not recruiting
• Conditions: COPD (Chronic Obstructive Pulmonary Disease)
• Intervention / Treatment: Other: Generic email - control; Other: Personalised email - Intervention

Detailed Description

Audit and feedback (A&F) is defined by Ivers et al. as the "provi(sion of) a recipient with a summary of their performance over a specified period of time" and has long history of use within a diverse area of research and business to promote clinician and organisational behaviour change. In healthcare, A&F has been used either alone, or as part of a composite quality improvement project (QIP), to improve health practitioner practice based on guidelines or targets. A 2012 Cochrane review systematically reviewed 140 papers on A&F spanning several decades and produced a meta-analysis showing an absolute risk difference (RD) in practitioners changing behaviour to comply with the preferred practice of 4.3% (interquartile range 0.5% to 16%). Their investigation emphasised that A&F is particularly effective when it is targeted specifically at prescribing practices (mean adj. RD 13.1% verses diabetes management 0.5%) and where baseline compliance is low.

Meta-regression of the Cochrane data showed that the effect size of A&F has remained largely unchanged over the last two decades of study, leading the authors to postulate that there is no longer reasonable clinical equipoise to question if A&F is effective. However, they also conclude that studies aiming to isolate how A&F can be utilised most effectively by comparing different A&F variations are few and far between and that this should be the target of future A&F research.

A&F has previously been used successfully within the West Yorkshire Clinical Commissioning Group (CCG) - now replaced by the NHS West Yorkshire Integrated Care Board (ICB) - to effect change on primary care prescribing practices. The ASPIRE cluster Randomised Controlled Trial (cRCT) of A&F in this region produced a reduction in risky prescribing (odds ratio 0.82), while the CROP quasi-experimental controlled interrupted time series analysis of A&F correlated with 15,000 fewer patients being inappropriately prescribed opioids over a period of a year compared to controls (35,36). Both studies utilised a similar A&F design, utilising a theoretical structure based around the Theoretical Domains Framework (TDF) that is ideal for determining the possible perceptions of interventions by its intended targets. They also operated the Behaviour Change Taxonomy (BCT) to describe their employed behavioural change techniques and their intended effects.

The combined Long-Acting Beta Agonist / Inhaled CorticoSteroid (LABA+ICS) inhaler category has been used to treat COPD patients who present with asthmatic features of partially reversible lung function in the past. The most recent Global Initiative for Chronic Obstructive Lung disease (GOLD) guidelines move away from this however, by actively suggesting their use should be discouraged in favour of LABA-Long-Acting-Muscarinic-Antagonist-ICS (LABA-LAMA-ICS) triple inhalers. This is based on two separated studies suggesting LABA-LAMA-ICS inhalers reduced exacerbations of COPD in a subset of patients compared to LABA-ICS. In 2018, an observational study in the UK suggested that LABA/ICS usage in the COPD population was approximately 20%.

Precision feedback is a concept that suggests that aligning feedback messaging to individual, objective performance and goals may improve the performance of audit and feedback to create change. Here we propose to use the opportunity provided by a pre-planned QIP into COPD prescribing in West Yorkshire to undertake a randomised controlled trial to address this question.

The study design is a Randomised Controlled Trial, which is taking place inside a pre-arranged quality improvement project (QIP) that will involve sending digital A&F feedback reports to all GP practices within West Yorkshire. The intervention element of this RCT will focus on the email that accompanies this digital A&F feedback reports, where primary care practices within the NHS West Yorkshire ICB region would be randomised to receive their digital A&F feedback reports alongside either personalised achievement emails, or generic emails only. All participants would take part in the pre-arranged QIP with or without this proposed research going ahead as it has already been agreed by the regional team. Therefore, randomisation will only affect the email that accompanies the A&F report. Once randomised, each practice will receive 7 A&F reports over the course of a year alongside their allocated intervention email format.

The personalised email wording will change based on the achievement of the practice and the content in the feedback reports, which is being distributed as part of the pre-existing QIP, rather than this research study. The recommendations in bullet points within the personalised emails suggesting how to improve care will be informed as relevant succinct summaries of the key guidance contained with the feedback reports, which will be based on either national guidelines or respected published literature. This will be written by the lead researcher for this project (who is the author of the QIP feedback reports themselves) and will be reviewed by the same group that reviews the QIP feedback report content before publication. The control email will be the same text each time for all practices within that arm and will contain no suggestions for improving practice. Examples of these intervention email types have been uploaded with this submission.

The outcome of this study will be a comparison between the proportion of patients with COPD on ICS/LABA inhalers within this primary care region. Secondary outcomes would look at the other markers of COPD prescribing selected for change in the QIP by the expert panel, as detailed in A11. Features that may influence the impact of the A&F intervention, including practice size, deprivation index, and respiratory disease burden will also be collected. Where available and when a formal data sharing agreement in the form of an organising information document has been signed, NHS Digital commissioning data for care of COPD patients that has been aggregated and pseudonymised at practice-level will also be supplied for analysis by West Yorkshire ICB.

Primary Care practices within NHS West Yorkshire ICB are already required to gain consent from patients to share patient data for quality improvement purposes. West Yorkshire ICB has a pre-arranged data sharing agreement with each individual GP practice for audit and feedback work, which includes permission to share the data with the University of Leeds. The pre-arranged, separate quality improvement project to improve COPD outcomes in the region through audit and feedback will involve the sharing of relevant patient data between primary care practices and the ICB. As part of this quality improvement project, the ICB will anonymise all patient level data, then aggregate this into a practice level data-point. Standard practice for this quality improvement project would then be for the ICB to pseudonymise this practice level data and share this data with the University of Leeds to aid with analysis. The only differences that this Randomised Controlled Trial adds to this process is that pseudonyms will be pre-arranged by the ICB for each practice. The research team will then randomise (using block randomisation via a simple computerised Random Number Generator) each practice pseudonym to receive their audit and feedback report alongside either a personalised achievement letter email, or a generic email. The research team will remain blinded to the identity of which practice has been assigned which pseudonym. However, clearly it is impossible for the ICB and the practices themselves to be blinded to the assignment status of each practice due to the nature of the intervention. The ICB will retain the process of sending out reports by email and post, as would be standard practice in such a quality improvement project.

• Study Type: Interventional
• Enrollment (Estimated): 270
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Leeds, United Kingdom
    • NHS West Yorkshire Integrated Care Board

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• All registered NHS primary care practices within the pre-planned COPD prescribing QIP that are within the boundary of the NHS West Yorkshire ICB will automatically be recruited as study participants.

Exclusion Criteria:

• Non-NHS primary care practices will be excluded as study participants.
• All prescribing outside of the primary care practice setting (such as that occurring through neighbourhood initiatives, hospice-based prescribers, or secondary care) will be excluded.
• Practices that opt-out of the pre-planned COPD prescribing QIP or are outside the boundary of the NHS West Yorkshire ICB.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Control GP practice group; A GP practice allocated to the control intervention within the West Yorkshire Integrated Care Board boundary, UK, that is taking part in the pre-planned COPD quality improvement project (ICONIC).	Other: Generic email - control; A generic email delivered to a GP practice alongside a digital feedback report. The generic control email will be the same text each time for all practices within that arm and will contain no suggestions for improving practice.
Experimental: Intervention GP practice group; A GP practice allocated to the personalised email intervention within the West Yorkshire Integrated Care Board boundary, UK, that is taking part in the pre-planned COPD quality improvement project (ICONIC).	Other: Personalised email - Intervention; A personalised achievement email delivered to a GP practice alongside a digital feedback report. The personalised email wording will change based on the achievement of the practice and the content in the feedback reports, which is being distributed as part of the pre-existing quality improvement project, rather than this research study. The recommendations in bullet points within the personalised emails suggesting how to improve care will be informed as relevant succinct summaries of the key guidance contained with the feedback reports, which will be based on either national guidelines or respected published literature. This will be written by the lead researcher for this project (who is the author of the QIP feedback reports themselves) and will be reviewed by the same group that reviews the QIP feedback report content before publication.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ICS/LABA inhaler use change.	The change in proportion of patients with COPD on ICS/LABA inhalers over the course of the intervention in each intervention group.	Post 1-year intervention relative to the baseline proportion.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post-bronchodilator test showing an FEV1/FVC ratio <0.7.	The change in proportion of people diagnosed with COPD in the last 2 years who have a post-bronchodilator test showing an FEV1/FVC ratio <0.7 over the course of the intervention in each intervention group.	Post 1-year intervention relative to the baseline proportion.
COPD exacerbations	The change in proportion of people with COPD with 2 or more COPD exacerbations in the last year - evidenced by courses of prednisolone - over the course of the intervention, within each intervention group.	Post 1-year intervention relative to the baseline proportion.
High-dose ICS-containing inhalers	The change in proportion of people with COPD prescribed high-dose ICS-containing inhalers over the course of the intervention in each intervention group.	Post 1-year intervention relative to the baseline proportion.

Collaborators and Investigators

• Sponsor: University of Leeds
• Investigators: Principal Investigator: Owen Thomas, MBBS; MSc, University of Leeds

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2025
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): January 4, 2027

Study Registration Dates

• First Submitted: September 2, 2025
• First Submitted That Met QC Criteria: September 16, 2025
• First Posted (Estimated): September 18, 2025

Study Record Updates

• Last Update Posted (Actual): January 15, 2026
• Last Update Submitted That Met QC Criteria: January 13, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: audit and feedback; Inhalers; implementation sciences
• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pathological Conditions, Signs and Symptoms; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 2025-NCT48

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data is not available for this study, only aggregate practice data, which will be shared on publication.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No